Citigroup
HRTX icon

Citigroup’s Heron Therapeutics HRTX Stock Holding History

Citigroup’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.79K Buy
7,240
+3,762
+108% +$4.36K ﹤0.01% 5223
2025
Q4 		$4.52K Sell
3,478
-2,473,051
-100% -$3.05M ﹤0.01% 5271
2025
Q3 		$3.12M Buy
2,476,529
+2,424,576
+4,667% +$3.84M ﹤0.01% 2324
2025
Q2 		$108K Sell
51,953
-29,889
-37% -$61K ﹤0.01% 4368
2025
Q1 		$180K Sell
81,842
-9,172
-10% -$17.8K ﹤0.01% 4261
2024
Q4 		$139K Buy
91,014
+5,031
+6% +$8.15K ﹤0.01% 4652
2024
Q3 		$171K Buy
85,983
+35,503
+70% +$84.8K ﹤0.01% 4445
2024
Q2 		$177K Buy
50,480
+33,017
+189% +$101K ﹤0.01% 3952
2024
Q1 		$48.4K Sell
17,463
-977
-5% -$2.46K ﹤0.01% 4639
2023
Q4 		$31.3K Buy
18,440
+18,230
+8,681% +$20.1K ﹤0.01% 4775
2023
Q3 		$217 Sell
210
-30,635
-99% -$43.6K ﹤0.01% 5312
2023
Q2 		$35.8K Buy
30,845
+20,412
+196% +$36.4K ﹤0.01% 4801
2023
Q1 		$15.8K Sell
10,433
-562
-5% -$1.41K ﹤0.01% 4583
2022
Q4 		$27.5K Sell
10,995
-546,097
-98% -$1.76M ﹤0.01% 4482
2022
Q3 		$2.35M Sell
557,092
-206,423
-27% -$808K ﹤0.01% 2035
2022
Q2 		$2.13M Buy
763,515
+612,908
+407% +$2.46M ﹤0.01% 2056
2022
Q1 		$861K Sell
150,607
-290,077
-66% -$2.12M ﹤0.01% 3107
2021
Q4 		$4.02M Buy
440,684
+244,403
+125% +$2.5M ﹤0.01% 2005
2021
Q3 		$2.1M Sell
196,281
-100,996
-34% -$1.23M ﹤0.01% 2506
2021
Q2 		$4.61M Buy
297,277
+50,038
+20% +$796K ﹤0.01% 1963
2021
Q1 		$4.01M Buy
247,239
+226,115
+1,070% +$4.03M ﹤0.01% 1951
2020
Q4 		$447K Buy
21,124
+15,114
+251% +$263K ﹤0.01% 4303
2020
Q3 		$89K Sell
6,010
-54,896
-90% -$857K ﹤0.01% 5203
2020
Q2 		$896K Sell
60,906
-1,491
-2% -$24.5K ﹤0.01% 3666
2020
Q1 		$733K Buy
62,397
+18,324
+42% +$344K ﹤0.01% 3501
2019
Q4 		$1.04M Sell
44,073
-102,745
-70% -$2.27M ﹤0.01% 3712
2019
Q3 		$2.72M Sell
146,818
-76,788
-34% -$1.41M ﹤0.01% 2533
2019
Q2 		$4.16M Buy
223,606
+209,439
+1,478% +$4.18M ﹤0.01% 2126
2019
Q1 		$346K Sell
14,167
-119,403
-89% -$3.13M ﹤0.01% 4558
2018
Q4 		$3.46M Buy
133,570
+129,411
+3,112% +$3.56M ﹤0.01% 2165
2018
Q3 		$131K Sell
4,159
-31,155
-88% -$1.16M ﹤0.01% 5651
2018
Q2 		$1.37M Sell
35,314
-220,595
-86% -$7.02M ﹤0.01% 3042
2018
Q1 		$7.06M Sell
255,909
-381,135
-60% -$8.65M 0.01% 1488
2017
Q4 		$11.5M Sell
637,044
-103,615
-14% -$1.69M 0.01% 1187
2017
Q3 		$12M Sell
740,659
-331,969
-31% -$5.21M 0.01% 1117
2017
Q2 		$14.9M Buy
1,072,628
+1,034,218
+2,693% +$15M 0.01% 897
2017
Q1 		$577K Sell
38,410
-176,173
-82% -$2.44M ﹤0.01% 3743
2016
Q4 		$2.81M Buy
214,583
+204,593
+2,048% +$3.21M ﹤0.01% 2533
2016
Q3 		$172K Sell
9,990
-1,357
-12% -$25.2K ﹤0.01% 4775
2016
Q2 		$205K Sell
11,347
-11,264
-50% -$220K ﹤0.01% 4479
2016
Q1 		$429K Buy
22,611
+14,925
+194% +$294K ﹤0.01% 4288
2015
Q4 		$205K Sell
7,686
-71,036
-90% -$1.9M ﹤0.01% 4722
2015
Q3 		$1.92M Buy
78,722
+75,181
+2,123% +$2.51M ﹤0.01% 2479
2015
Q2 		$110K Sell
3,541
-202
-5% -$3.8K ﹤0.01% 4919
2015
Q1 		$54K Sell
3,743
-2,631
-41% -$29.7K ﹤0.01% 5498
2014
Q4 		$64K Buy
6,374
+5,528
+653% +$45.1K ﹤0.01% 5530
2014
Q3 		$7K Buy
846
+641
+313% +$5.97K ﹤0.01% 6419
2014
Q2 		$3K Buy
205
+136
+197% +$1.63K ﹤0.01% 6629
2014
Q1 		$1K Buy
+69
New +$922 ﹤0.01% 6860

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Citigroup's HRTX Position: Q1 2026 in Review

Citigroup increased its Heron Therapeutics (HRTX) stake by 108% in Q1 2026, buying an estimated $4.36K and bringing the position to 7,240 shares worth $5.79K. The position accounts for ﹤0.01% of the portfolio, ranked #5223.

Citigroup first reported a position in HRTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $14.9M in Q2 2017. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Citigroup held 7,240 shares of Heron Therapeutics worth $5.79K as of Q1 2026.
  • Citigroup bought 3,762 Heron Therapeutics shares in Q1 2026, an estimated $4.36K.
  • Heron Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5223 holding.
  • Citigroup first reported a position in Heron Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Citigroup's Heron Therapeutics position peaked at $14.9M in Q2 2017.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.